Publications
1- Yazici Y, Erkan D, Harrison MJ, Peterson M, Yazici H. Reporting consistency in systemic lupus erythematosus patients: How reliable are patient histories? Lupus 2002; 11: 46-8. 2- Yazici Y, Erkan D, Lockshin MD. Etanercept in the treatment of severe, resistant psoriatic arthritis: Continued efficacy and changing patterns of use after 2 years. Clinical and Experimental Rheumatology 2002; 20: 115. 3- Yazici Y, Erkan D, Levine DM, Parker TS, Lockshin MD. Protein losing enteropathy in systemic lupus erythematosus: Report of a severe, persistent case and review of pathophysiology. Lupus 2002; 11: 119-123. 4- Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. Reply. (High thrombosis rate after fetal loss in antiphospholipid syndrome - Effective prophylaxis with aspirin. Arthritis and Rheumatism 2001; 44: 1466-7) Arthritis and Rheumatism 2002; 46: 1127. 5- Yazici Y, Erkan D, Kulman I, Belostocki K, Harrison MJ. Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: Further evidence of clinical effectiveness in the “real world”. Annals of the Rheumatic Diseases 2002; 61: 638-640. 6- Erkan D, Yazici Y, Harrison MJ, Paget SA. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: The impact of cost on first line therapy. Arthritis and Rheumatism (Arthritis Care and Research) 2002; 47: 285-290. 7- Yazici Y, Erkan D, Paget SA. Monitoring for methotrexate hepatic toxicity in rheumatoid arthritis patients: Is it time to update the guidelines? Journal of Rheumatology 2002; 29: 1586-1589. 8- Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 2002; 41:924-929. 9- Yazici Y, Erkan D, Paget SA. Inflammatory musculoskeletal disorders in the elderly: Part I. The Journal of Musculoskeletal Medicine 2002; 19: 265-276.
|
